Skip to main content
Fig. 4 | Orphanet Journal of Rare Diseases

Fig. 4

From: Olipudase alfa enzyme replacement therapy for acid sphingomyelinase deficiency (ASMD): sustained improvements in clinical outcomes after 6.5 years of treatment in adults

Fig. 4

Assessment of interstitial lung disease by high-resolution computed tomography (HRCT). Mean HRCT scores over time for ground glass appearance, interstitial lung disease, and reticulo-nodular density. Scoring is based on a 4-point system where 0 = No disease; 1 = Mild (affecting 1–25% of the lung volume); 2 = Moderate (affecting 26–50% of the lung volume); 3 = Severe (affecting 51–100% of the lung volume)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172